Today's Breaking News
- FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
- Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
- Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
Latest R&D and Business News
- Neurelis announces first healthy subjects dosed in investigational study of NRL-1049, a Rho kinase (ROCK) inhibitor with potential to treat cerebral cavernous malformations
- OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia
- ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates
- Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
- BLA Accepted in China for Boan Biotech's Denosumab Injection (BA1102) for the Oncology Indications
- Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
- Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
- Debiopharm announces launch of the phase 1/2 GaLuCi™ study for its CA IX-targeted radiopharmaceutical program
- Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody
- Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series
- Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial
- Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation